Abstract:Abstract Therapy resistance is responsible for 90% of cancer-related deaths. We identified a novel mechanism of therapy resistance in which cancer cells enter an endocycling cell state, undergoing repeated S and G phases without dividing. As a result, resistant endocycling cells are 40 times larger than mitotic cancer cell controls. Interestingly, we observed that these non-proliferative endocycling cells can eventually give rise to proliferative progeny weeks after chemotherapy is removed, modeling cancer recurrence. We hypothesize that this endocycling cancer cell state is a critical driver of therapy resistance and cancer lethality. We evaluated oxidative stress in endocycling cells that survived the days and weeks following chemotherapy treatment using DCF-DA staining. We found increased levels of reactive oxygen species (ROS) in endocycling prostate cancer cells compared to untreated mitotic cells when normalized to cell size. Given that mitochondria are major producers and regulators of ROS, we hypothesize that cells surviving in this resistant state alter mitochondrial structure and function in response to increased oxidative stress. We performed immunofluorescence and confocal microscopy on mitochondria in untreated cells and cells following chemotherapy treatment to observe their morphology. Surviving endocycling cells had increased mitochondrial fragmentation when compared to the untreated group, a result that was further supported by reduced expression of phospho-DRP1 Ser637 via western blot. To assess changes in glucose metabolism, we then utilized isotope tracing-based metabolomics with [U-13C]glucose on untreated and surviving endocycling cells following chemotherapy. Endocycling cells had decreased labeling of 13C in TCA cycle metabolites, suggesting a decrease in mitochondrial function when compared to untreated cells. Ongoing work involves further studying metabolic reprogramming as cells enter this resistant state with parallel labeling experiments using [1,2-13C]glucose and [U-13C]glutamine to perform mathematical modeling-based 13C-metabolic flux analysis. In addition, we engineered a cell line to track mitochondria in real-time to quantify mitochondrial dynamics underlying the morphology observed in untreated and surviving cells. Our goal is to characterize how this therapy-resistant cell state alters its mitochondrial structure and function to survive therapeutic stress. Identifying vulnerabilities of this phenotype will enable new approaches for eliminating drug resistance in cancer. Citation Format: Melvin Li, Sarah R. Amend, Kenneth J. Pienta. Therapy-resistant endocycling cancer cells alter mitochondrial structure and metabolism to survive therapeutic stress [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6612.

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy

Abstract A52: Overcoming Mitochondrial Oxidative Phosphorylation-Mediated Resistance to Targeted Therapies in Melanoma

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Targeting Mitochondria in Melanoma

Mitochondria in colorectal cancer stem cells - a target in drug resistance

Targeting mitochondrial metabolism for metastatic cancer therapy

Abstract 6612: Therapy-resistant endocycling cancer cells alter mitochondrial structure and metabolism to survive therapeutic stress

Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells

A novel mitochondria‐targeting compound exerts therapeutic effects against melanoma by inducing mitochondria‐mediated apoptosis and autophagy in vitro and in vivo

Targeting Therapy with Mitosomal Daunorubicin Plus Amlodipine Has the Potential to Circumvent Intrinsic Resistant Breast Cancer

PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism

Mitochondrial Targeting Topotecan-Loaded Liposomes for Treating Drug-Resistant Breast Cancer and Inhibiting Invasive Metastases of Melanoma.

Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer

Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS -mutant lung cancer

Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance

Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance

Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?